Molecular Therapy Nucleic Acids Impact Factor, Quartile, Indexing, Ranking

Molecular Therapy Nucleic Acids (MrNA) is a scholarly journal dedicated to publishing research in the field of Pharmacology, Toxicology and Pharmaceutics, and Published by Cell Press. and its abbreviation is Mol Ther Nucleic Acids.

The Publicaiton fees (APC) is £3,120, €3,490, $3,900, for non member, £2,560, €2,864, $3,200 for society members.

Molecular Therapy Nucleic Acids is an international, open-access journal publishing top-quality basic, translational, and clinical research in the broad fields of nucleic-acid-based therapeutics to treat and/or correct genetic and acquired disease. As an official journal of the American Society of Gene & Cell Therapy, Molecular Therapy Nucleic Acids builds upon the success of Molecular Therapy in publishing important peer-reviewed research, cutting-edge reviews, and commentaries targeted to advances in gene- and oligonucleotide-based therapies.

Subject areas include but are not limited to: development of therapeutics based on nucleic acids and their derivatives, vector development and design for the delivery of RNA-based therapeutics, applications of gene-modifying agents including triplex-forming oligonucleotides and enzymes such as Zn finger nucleases, pre-clinical target validation, safety/efficacy studies, and clinical trials.

• Journal Website
• PubMed
• Scopus
• SCImago